Loading
Neoplasm Invasiveness / Tumor Microenvironment / Neoplasm Metastasis · Journal article
Cancer Biology & Therapy · August 11, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes current knowledge on platelet-tumor cell interactions and their role in metastasis, proposing platelets as potential liquid biopsy biomarkers and therapeutic targets. The source summarizes mechanistic evidence and identifies research gaps but does not report original data, clinical trial results, or quantified clinical endpoints.
Journal article. Cancer patients (discussed in context of metastasis and progression)..
Platelets undergo measurable alterations in count, mean platelet volume, and molecular cargo (proteins and mRNAs) in bidirectional interactions with cancer cells. Within the tumor microenvironment, platelets support immune evasion, tumor cell intravasation and extravasation, circulating tumor cell survival, and neovascularization. Platelets can physically shield malignant cells from immune surveillance, increasing metastatic potential.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies platelets as a candidate biomarker and therapeutic target for cancer risk stratification and prognostic evaluation. Clinicians and researchers should recognize this as a state-of-knowledge synthesis identifying mechanistic hypotheses and research priorities rather than evidence for clinical implementation.
This is a narrative review synthesizing mechanistic evidence on platelet-tumor interactions without reporting primary experimental or clinical data, clinical endpoints, or quantified effect sizes.
This review identifies platelets as a candidate biomarker and therapeutic target for cancer risk stratification and prognostic evaluation. Clinicians and researchers should recognize this as a state-of-knowledge synthesis identifying mechanistic hypotheses and research priorities rather than evidence for clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Platelets, traditionally recognized for their role in hemostasis, are now understood to actively contribute to tumor progression, angiogenesis, and metastasis. Through dynamic bidirectional interactions with cancer cells, platelets undergo measurable alterations in count, mean platelet volume, and molecular cargo, including proteins and mRNAs, supporting their potential utility as liquid biopsy biomarkers for early cancer detection. Within the tumor microenvironment, platelets contribute to immune evasion, support tumor cell intravasation and extravasation, enhance the survival of circulating tumor cells, and promote neovascularization. In addition, they can physically shield malignant cells from immune surveillance, thereby increasing metastatic potential. Although context-specific anti-tumor effects have been reported, the predominant evidence supports a largely pro-tumorigenic and pro-metastatic role for platelets. Elucidating the molecular mechanisms underlying platelet-tumor interactions is therefore essential for improving cancer risk stratification, prognostic evaluation, and therapeutic development. This review summarizes current advances in platelet-derived biomarkers and discusses emerging therapeutic strategies targeting platelet-mediated pathways to suppress metastasis and improve clinical outcomes in cancer patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.